Sign In
Buy RLMD
$6.33
-0.0900 (-1.40%)
At Close: Jun 03, 2026
Steven Cohen's Firm Boosts Stakes in Relmada and Immunic
05:52pm, Tuesday, 25'th Oct 2022
Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) a
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
02:18pm, Friday, 14'th Oct 2022
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Why Is Relmada (RLMD) Stock Down 78% Today?
10:06am, Thursday, 13'th Oct 2022
Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD ) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial. Unfortunately for RLMD stock, its RELIANCE III st
Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges
09:25am, Thursday, 13'th Oct 2022
Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.
Relmada's stock tumbles 80% after its depressive disorder drug failed a late-stage study
08:00am, Thursday, 13'th Oct 2022
Shares of Relmada Therapeutics Inc. RLMD, -0.97% fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not me
Relmada Therapeutics: Central Nervous System Treatments
03:34pm, Wednesday, 28'th Sep 2022
100% technical buy signals. 8 new highs and up 15.55% in the last month.
Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
12:19am, Wednesday, 14'th Sep 2022
We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid,
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q2 2022 Results - Earnings Call Transcript
09:39am, Sunday, 14'th Aug 2022
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer Jo
Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
08:30am, Friday, 05'th Aug 2022
CORAL GABLES, Fla. , Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announce
Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
08:30am, Tuesday, 07'th Jun 2022
CORAL GABLES, Fla. , June 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics, Inc.'s (RLMD) CEO Sergio Traversa on Q1 2022 Results - Earnings Call Transcript
11:27am, Sunday, 08'th May 2022
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors, Investor Relations Sergio Traversa - Chief Execu
Here's Why Relmada Therapeutics Shares Are Rising
01:55pm, Thursday, 24'th Mar 2022
Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results. Relmada Therapeutics reported quarterly
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2021 Results - Earnings Call Transcript
08:08pm, Wednesday, 23'rd Mar 2022
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2021 Results - Earnings Call Transcript
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022
08:30am, Wednesday, 16'th Mar 2022
CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc
Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential
11:42am, Wednesday, 23'rd Feb 2022
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor
